eyonis Inc., a Median Technologies Company, to Present Study Results Supporting eyonis® LCS Performance Claims at CHEST 2026
For best results when printing this announcement, please click on link below: eyonis Inc., a Median Technologies Company, to Present Study Results Supporting eyonis® LCS Performance Claims at CHEST 2026 Study demonstrated 93.3% sensitivity, 92.4% specificity and 99.9% negative predictive value for eyonis® LCS eyonis® L